331 related articles for article (PubMed ID: 12734765)
1. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
3. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
4. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG
Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505
[TBL] [Abstract][Full Text] [Related]
5. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
Kang SG; Choi JE; An H; Lim SW; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Lee MS; Joe SH; Jung IK; Kim L
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1545-8. PubMed ID: 18602732
[TBL] [Abstract][Full Text] [Related]
6. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK
Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
8. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].
Gałecki P; Pietras T; Szemraj J
Psychiatr Pol; 2006; 40(5):937-48. PubMed ID: 17217237
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
10. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
11. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia.
Pae CU; Kim TS; Patkar AA; Kim JJ; Lee CU; Lee SJ; Jun TY; Lee C; Paik IH
Psychiatry Res; 2007 Sep; 153(1):77-81. PubMed ID: 17582511
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
[TBL] [Abstract][Full Text] [Related]
13. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
[TBL] [Abstract][Full Text] [Related]
14. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Paik JW; Lee MS; Cho BH; Park YM; Kim W; Choi JE; Jung IK; Kim L; Lee MS
Hum Psychopharmacol; 2007 Dec; 22(8):501-4. PubMed ID: 17726725
[TBL] [Abstract][Full Text] [Related]
15. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
Go CL; Rosales RL; Caraos RJ; Fernandez HH
Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
[TBL] [Abstract][Full Text] [Related]
17. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
Kang SG; Lee HJ; Choi JE; An H; Rhee M; Kim L
Hum Psychopharmacol; 2009 Jan; 24(1):55-60. PubMed ID: 19051221
[TBL] [Abstract][Full Text] [Related]
18. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
[TBL] [Abstract][Full Text] [Related]
20. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
